The pioglitazone safety warning issued in South Korea, which recommended prescribing with careful attention among those with high risk of bladder cancer, led to a moderate decrease in pioglitazone users.
Han Eol Jeong, MPH
Advertisement
Articles by Han Eol Jeong, MPH
Advertisement
Latest Updated Articles
- Prescribing Trend of Pioglitazone After Safety Warning Release in Korea
November 19th 2019
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
3
Regorafenib Prescribing in Advanced GIST Deviates From Guidelines
4
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
5